Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22619849 | 0.87 | TDP2 (0.54) | TDP2LMNAALDH1A1PKMKDM4E | |
| SCHEMBL408390 | 0.85 | TDP2 (0.52) | TDP2LMNAALDH1A1PKMKDM4E | |
| SCHEMBL405325 | 0.84 | S1PR1 (0.46) | KDM4ES1PR1S1PR3GABRA5 | |
| SCHEMBL409143 | 0.83 | TDP2 (0.50) | TDP2LMNAALDH1A1PKMKDM4E | |
| SCHEMBL404315 | 0.82 | TDP2 (0.49) | TDP2LMNAALDH1A1PKMKDM4E | |
| SCHEMBL31587044 | 0.82 | ADORA3 (0.50) | TDP2LMNAALDH1A1PKMKDM4E | |
| SCHEMBL409115 | 0.79 | S1PR1 (0.43) | TDP2ALDH1A1KDM4EHSD17B10S1PR1 | |
| SCHEMBL9722632 | 0.78 | LMNA (0.50) | TDP2LMNAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL409026 | 0.74 | S1PR1 (0.47) | KDM4ES1PR1S1PR3GABRA5 | |
| SCHEMBL10111574 | 0.74 | LMNA (0.49) | TDP2LMNAALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2389377-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Bristol-Myers Squibb Company (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8038731-B2 | hair dyes contains naphthylimide thiol or disulphide groups; resistant and visible lightening effect on dark keratin fibres; cosmetics | L'OREAL S.A. (FR) | 2011-10-18 | — | — | US | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | S1PR1, S1PR4, S1PR3 | TDP2 2467/4885LMNA 3234/4885ALDH1A1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.